VELTANE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELTANE (VELTANE).
Veltane is a prodrug of bendamustine, an alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to apoptosis.
| Metabolism | Veltane (bendamustine hydrochloride) is primarily metabolized via hydrolysis to monohydroxy and dihydroxy metabolites. Minor metabolism occurs through CYP1A2, resulting in active metabolites (gamma-hydroxybendamustine and N-desmethylbendamustine). |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites |
| Half-life | Terminal elimination half-life: 12 hours; steady-state reached after 2-3 days |
| Protein binding | 92% primarily bound to albumin |
| Volume of Distribution | 1.2 L/kg; indicates extensive extravascular distribution |
| Bioavailability | Oral: 85% |
| Onset of Action | Oral: 1 hour; IV: 5 minutes |
| Duration of Action | Oral: 12-24 hours; IV: 6-12 hours; dosing interval adjusted based on renal function |
Adults: 5 mg orally once daily, with or without food.
| Dosage form | Tablet |
| Renal impairment | eGFR 30-89 mL/min: No adjustment. eGFR 15-29 mL/min: 2.5 mg once daily. eGFR <15 mL/min or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | Initial dose 2.5 mg once daily; titrate based on response and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VELTANE (VELTANE).
| Breastfeeding | Excreted into breast milk (M/P ratio 0.8). American Academy of Pediatrics: Compatible but caution due to potential adverse effects on infant renal function and platelet aggregation. Avoid high doses, monitor infant for diarrhea, rash, drowsiness; alternative preferred. |
| Teratogenic Risk | First trimester: Crosses placenta; fetal risk cannot be excluded; human data limited, animal studies show increased congenital malformations (skeletal, cardiovascular) at supratherapeutic doses. Second/third trimester: No evidence of specific end-organ toxicity; theoretical risk of premature ductus arteriosus closure (prefers COX-2 selectivity). Overall: Class D if used >20 weeks, avoid first trimester if possible. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to bendamustine or mannitol.
| Precautions | Myelosuppression (neutropenia, thrombocytopenia, anemia), infections, infusion reactions, tumor lysis syndrome, skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), hepatotoxicity, and fetal harm. |
Loading safety data…
| Fetal Monitoring | Fetal ultrasound for growth and anatomy at 18-20 weeks, serial growth scans if prolonged therapy; amniotic fluid index assessment; maternal blood pressure, renal function (creatinine, BUN), liver enzymes (ALT, AST) at baseline and monthly; platelet count if high dose. |
| Fertility Effects | Reversible inhibition of ovulation due to altered prostaglandin synthesis in Graafian follicle; no long-term fertility impairment; may delay return to fertility; men: no significant effect on spermatogenesis. |